A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus(SELINA Study)
Phase of Trial: Phase IV
Latest Information Update: 18 Jan 2019
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms SELINA
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 15 Nov 2017 Status changed from active, no longer recruiting to completed.
- 16 Aug 2017 Status changed from recruiting to active, no longer recruiting.